CYP3A5 *1 Allele: Impacts on Early Acute Rejection and Graft Function in Tacrolimus-Based Renal Transplant Recipients

• DOI: 10.1097/tp.0b013e3181fa93a4
• Publication Date: 2010-11-13T09:20:09Z
• Authors: Sang-Il Min; Seong Yup Kim; Sang Hyun Ahn; Seung-Kee Min; Si Hwa Kim; Yon Su Kim; Kyung Chul Moon; Jung Mi Oh; Sang Joon Kim; Jongwon Ha
• Keywords: Immunosuppressive drug

Background. Tacrolimus is a major immunosuppressant, which has narrow therapeutic range and wide interindividual variation. The effects of genetic polymorphisms cytochrome P450 3A (CYP3A) 5 Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) genes on the achievement target tacrolimus trough levels clinical outcomes in renal transplants were evaluated. Methods. A total 62 patients participated this prospective study. After an initial fixed oral dose (0.08 mg/kg two times per day), doses adjusted to based daily measurement blood concentration. Every patient underwent 10-day scheduled biopsy. Both investigators blinded for polymorphisms. Results. Those subjects expressing CYP3A5 (n=29) evidenced significantly lower between days after transplantation, when compared with nonexpressers (n=33). Significantly higher overall incidences early T-cell-mediated rejection (TCR) at least Banff grade severity (P=0.017), including within 10 subclinical biopsies postoperative day detected expressers. TCR according '07 classification was associated genotypes (P=0.012). Moreover, multivariate analysis identified expression as independent risk factor (odds ratio: 2.79; P=0.043). estimated glomerular filtration rates until month numerically by 12 months noted ABCB1 exerted no significant effects. Conclusion. We confirmed polymorphism development acute period transplantation consequent allograft function.